AI-Generated Digital Twins in ALS: Improving Confidence in Early-Stage Studies
Time: 2:00 pm
day: Conference Day One Track B PM
Details:
- PRO-101 – Study Overview: a Phase 1 clinical trial evaluating prosetin—a first-in-class MAP4 kinase (MAP4K) inhibitor
- AI-Powered Digital Twins in – PRO-101 – Enhancing data robustness and interpretation in ALS studies
- Using Digital Twins as an External Control – Leveraging AI to support early-stage data analysis for more informed decisionmaking